Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

Arthritis Research and Therapy

Volumn 10, Issue 5, 2008, Pages

  Nannini, Carlotta ^a   West, Colin P ^a   Erwin, Patricia J ^a   Matteson, Eric L ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PLACEBO; PREDNISONE; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG FUNCTION; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; LUNG; LUNG FUNCTION TEST;

CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 55749093240     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2534     Document Type: Review

References (33)

1. Tashkin DP Elashoff R Clements PJ Goldin J Roth MD Furst DE Arriola E Silver R Strange C Bolster M Seibold JR Riley DJ Hsu VM Varga J Schraufnagel DE Theodore A Simms R Wise R Wigley F White B Steen V Read C Mayes M Parsley E Mubarak K Connolly MK Golden J Olman M Fessler B Rothfield N Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 2006, 354:2655-2666. 10.1056/NEJMoa055120 16790698
2. Van Laar JM Stolk J Tyndall A Scleroderma lung. Pathogenesis, evaluation and current therapy Drugs 2007, 67:985-996. 10.2165/ 00003495-200767070-00004 17488144
3. Bérezné A Valeyre D Ranque B Guillevin L Mouthon L Interstitial lung disease associated with systemic sclerosis. What is the evidence for efficacy of cyclophosphamide? Ann N Y Acad Sci 2007, 1110:271-284. 17911442 10.1196/annals.1423.029
4. Strange C Highland KB Interstitial lung disease in the patient who has connective tissue disease Clin Chest Med 2004, 25:549-559. 10.1016/ j.ccm.2004.05.009 15331191
5. White B Interstitial lung disease in scleroderma Rheum Dis Clin North Am 2003, 29:371-390. 12841300 10.1016/S0889-857X(03)00025-5
6. Latsi PI Wells AU Evaluation and management of alveolitis and interstitial lung disease in scleroderma Curr Opin Rheumatol 2003, 15:748-755. 10.1097/00002281-200311000-00011 14569205
7. Zandman-Goddard G Tweezer-Zaks N Shoenfeld Y New therapeutic strategies for systemic sclerosis: A critical analysis of the literature Clin Dev Immunol 2005, 12:165-173. 2275417 16295521 10.1080/17402520500233437
8. Cochrane Website http://www.cochrane.org/resources/handbook/index.htm
9. Moher D Cook DJ Eastwood S Olkin I Rennie D Stroup DF Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. QUOROM Group Br J Surg 2000, 87:1448-1454. 10.1046/ j.1365-2168.2000.01610.x 11091231
10. Hoyles RK Ellis RW Wellsbury J Lees B Newlands P Goh NS Roberts C Desai S Herrick AL McHugh NJ Foley NM Pearson SB Emery P Veale DJ Denton CP Wells AU Black CM du Bois RM A multicenter, prospective, randomized, double blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 2006, 54:3962-3970. 10.1002/art.22204 17133610
11. Nadashkevich O Davis P Fritzler M Kovalenko W A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis Clin Rheumatol 2006, 25:205-212. 10.1007/ s10067-005-1157-y 16228107
12. Davas EM Peppas C Maragou M Alvanou E Hondros D Dantis PC Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma Clin Rheumatol 1999, 18:455-461. 10.1007/ s100670050138 10638770
13. White B Moore WC Wigley FM Xiao HQ Wise RA Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 2000, 132:947-954. 10858177
14. Beretta L Caronni M Raimondi M Ponti A Viscuso T Origgi L Scorza R Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience in one centre Clin Rheumatol 2007, 26:168-172. 10.1007/s10067-006-0254-x 16614793
15. Airò P Danieli E Rossi M Frassi M Cavazzana I Scarsi M Grottolo A Franceschini F Zambruni A Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: Results with an 18 month long protocol including a maintenance phase Clin Exp Rheumatol 2007, 25:293-296. 17543156
16. Pakas I Ioannidis JP Malagari K Skopouli FN Moutsopoulos HM Vlachoyiannopoulos PG Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease J Rheumatol 2002, 29:298-304. 11842824
17. Silver RM Warrick JH Kinsella MB Staudt LS Baumann MH Strange C Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease J Rheumatol 1993, 20:838-844. 8336309
18. Valentini G Paone C La Montagna G Chiarolanza I Menegozzo M Colutta E Ruocco L Low-dose intravenous cyclophosphamide in systemic sclerosis: An open prospective efficacy study in patients with early diffuse disease Scand J Rheumatol 2006, 35:35-38. 10.1080/03009740510026896 16467039
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510 7378088
20. American Thoracic Society, European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 Am J Resp Crit Care Med 2002, 165:277-304. 11790668
21. Guidelines for the measurement of respiratory function: Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists Respir 1994, 88:165-194. 8209067 10.1016/ S0954-6111(05)80346-4
22. Jadad AR Moore RA Carroll D Jenkinson C Reynolds DJ Gavaghan DJ McQuay HJ Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996, 17:1-12. 10.1016/ 0197-2456(95)00134-4 8721797
23. Wells GA Shea B O'Connell D The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis Proceedings of the Third Symposium on Systematic Reviews: Behind the Basics Oxford. England http://www.ohri.ca/programs/clinical_epidemiology/ oxford.htm July 4-9. 2000
24. Kazerooni EA Martinez FJ Flint A Jamadar DA Gross BH Spizarny DL Cascade PN Whyte RI Lynch JP 3rd Toews G Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring AJR Am J Roentgenol 1997, 169:977-983. 9308447
25. Cohen J A power primer Psychol Bull 1992, 112:155-159. http://psycnet.apa.org/index.cfm?fa=search.displayRecord&uid= 1992-37683-001 10.1037/0033-2909.112.1.155
26. Steen VD Lanz JK Jr Conte C Owens GR Medsger TA Jr Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study Arthritis Rheum 1994, 37:1290-1296. 7945491 10.1002/art.1780370904
27. Tashkin DP Elashoff R Clements PJ Roth MD Furst DE Silver RM Goldin J Arriola E Strange C Bolster MB Seibold JR Riley DJ Hsu VM Varga J Schraufnagel D Theodore A Simms R Wise R Wigley F White B Steen V Read C Mayes M Parsley E Mubarak K Connolly MK Golden J Olman M Fessler B Rothfield N et al Effect of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease Am J Respir Crit Care Med 2007, 176:1026-1034. 10.1164/rccm.200702-326OC 17717203
28. Giacomelli R Valentini G Salsano F Cipriani P Sambo P Conforti ML Fulminis A De Luca A Farina G Candela M Generini S De Francisci A Tirri E Proietti M Bombardieri S Gabrielli A Tonietti G Cerinic MM Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis J Rheumatol 2002, 29:731-736. 11950014
29. Plotz PH Klippel JH Decker JL Grauman D Wolff B Brown BC Rutt G Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus and rheumatoid arthritis Ann Intern Med 1979, 91:221-223. 464465
30. Talar-Williams C Hijazi YM Walther MM Linehan WM Hallahan CW Lubensky I Kerr GS Hoffman GS Fauci AS Sneller MC Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegner granulomatosis Ann Intern Med 1996, 124:477-484. 8602705
31. Knight A Askling J Granath F Sparen P Ekbom A Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide Ann Rheum Dis 2004, 63:1307-1311. 1754772 15130900 10.1136/ard.2003.019125
32. Griffiths B Miles S Moss H Robertson R Veale D Emery P Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function J Rheumatol 2002, 29:2371-2378. 12415594
33. Pai BS Srinivas CR Sabitha L Shenoi SD Balachandran CN Acharya S Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis Int J Dermatol 1995, 34:726-728. 10.1111/ j.1365-4362.1995.tb04664.x 8537165